Effects of lactobacillus rhamnosus strain gg in pediatric obesity-related liver disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 52, Issue 6, 2011, Pages 740-743

  Vajro, Pietro ^a,b   Mandato, Claudia ^c   Licenziati, Maria Rosaria ^c   Franzese, Adriana ^a   Vitale, Dino Franco ^d   Lenta, Selvaggia ^a   Caropreso, Maria ^a   Vallone, Gianfranco ^a   Meli, Rosaria ^b  

^a Department of Pediatrics ^*  (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

^d IRCCS   (Italy)

Author keywords

Children; Lactobacillus GG; liver; nonalcoholic fatty liver disease; probiotics

Indexed keywords

ALANINE AMINOTRANSFERASE; LACTOBACILLUS RHAMNOSUS STRAIN GG; PEPTIDOGLYCAN POLYSACCHARIDE; PLACEBO; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; BACTERIAL STRAIN; BODY MASS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; FEMALE; HUMAN; HYDROGEN BREATH TEST; HYPERTRANSAMINASEMIA; INTRAABDOMINAL FAT; LACTOBACILLUS RHAMNOSUS; LIFESTYLE MODIFICATION; LIVER DISEASE; LIVER FUNCTION TEST; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT REFUSAL;

LACTOBACILLUS; LACTOBACILLUS RHAMNOSUS; RODENTIA;

EID: 85027931445     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31821f9b85     Document Type: Article

References (30)

1. Yanovski SZ, Yanovski JA. Obesity prevalence in the United States\up, down, or sideways? N Engl J Med 2011;364:987-9.
2. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011 Apr 11 [Epub ahead of print].
3. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388-93. (Pubitemid 46393782)
4. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997;42:1428-32. (Pubitemid 27339358)
5. St George A, Bauman A, Johnston A, et al. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol 2009;24:399-407.
6. Nobili V, Alisi A, Raponi M. Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. World J Gastroenterol 2009;15:6017-22.
7. Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010;28:155-61.
8. Caldwell S, Argo C The natural history of non-alcoholic fatty liver disease. Dig Dis 2010;28:162-8.
9. Musso G, Gambino R, Cassader M, et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104.
10. Socha P, Horvath A, Vajro P, et al. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009;48:587-96.
11. Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal overgrowth, intestinal permeability, endotoxaemia, and tumor necrosis factor a in the pathogenesis of non alcoholic steatohepatitis. Gut 2001;48:206-11. (Pubitemid 32141844)
12. Sabaté JM, Jouët P, Harnois F, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008;18:371-7.
13. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-87.
14. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343-50. (Pubitemid 36152533)
15. Esposito E, Iacono A, Bianco G, et al. Probiotics reduce the inflam-matory response induced by a high-fat diet in the liver of young rats. J Nutr 2009;139:905-11.
16. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005;39:540-3. (Pubitemid 40863651)
17. Solga SF, Buckley G, Clark JM, et al. The effect of a probiotic on hepatic steatosis. J Clin Gastroenterol 2008;42:1117-9.
18. Sabir N, Sermez Y, Kazil S, et al. Correlation of abdominal fat accumulation and liver steatosis: importance of ultrasonographic and anthropometric measurements. Eur J Ultrasound 2001;14:121-8. (Pubitemid 33026505)
19. Vajro P, Fontanella A, Perna C, et al. Persistent hyperaminotransfer- asemia resolving after weight reduction in obese children. J Pediatr 1994;125:239-41. (Pubitemid 24253007)
20. Mancini M, Prinster A, Annuzzi G, et al. Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with (1)H magnetic resonance spectroscopy. Metabolism 2009;58:1724-30.
21. Gasbarrini A, Corazza GR, Gasbarrini G, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference.Aliment Pharmacol Ther2009;29(suppl1):1-49.
22. Hazenberg MP, de Visser H, Bras MJ, et al. Serum antibodies to peptidoglycan-polysaccharide complexes from the anaerobic intestinal flora in patients with Crohn's disease. Digestion 1990;47:172-80.
23. Schrijver IA, DeMan YA, Melief MJ, et al. Reducedsystemic Ig Glevels against peptidoglycan in rheumatoid arthritis (RA) patients. Clin Exp Immunol 2001; 123: 140-6. (Pubitemid 32118850)
24. Lichtman SN, Keku J, Schwab JH, et al. Evidence for peptidoglycan absorption in rats with experimental small bowel bacterial overgrowth. Infect Immun 1991;59:555-62.
25. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 1988;8:232-6.
26. Harte AL, da Silva NF, Creely SJ, et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 2010;7:15.
27. Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009;49:989-97.
28. Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol 2009;587:4153-8.
29. Riordan SM, Duncombe VM, Thomas MC, et al. Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steato-hepatitis. Gut 2002;50:136-8.
30. Abu-Shanab A, Quigley EM. The role of the gut microbiota in non-alcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7:691-701.